ClinicalTrials.gg

Alopecia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 512 studies for Alopecia across more than 10 countries. 129 are recruiting or about to start. 440 of them are mainly about Alopecia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Alopecia Areata: 697 studies, 177 open.

ClinicalTrials.gov finds 742 studies for Alopecia. How that becomes 509 here

This page counts the studies the registry files under Alopecia, and those it files under no condition that list Alopeciathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 742Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −185Filed under a narrower condition, counted on its own pageAlopecia Areata 183 · Alopecia universalis 2
  3. −11List Alopecia as a condition, but the registry did not file them under itMost often written as “Chemotherapy-induced Alopecia” (4), “Frontal Fibrosing Alopecia” (3), and “Chemotherapy Induced Alopecia” (1). The registry filed them under other conditions only, most often Breast Neoplasms (5) and Lichen Planus (4).
  4. −37Match it another way22 name it in the title, 2 in a keyword, and 13 by a synonym or other text the search reads.
  5. 509The count on this page35 of them list Alopecia in their own words; the registry filed them under no condition.

Status

Completed
244
Recruiting
75
Status unknown
56
Not yet recruiting
47
Active, not recruiting
35
Withdrawn
26

Phase

Phase 2
123
Phase 1
60
Phase 3
56
Phase 4
19
Early Phase 1
19

Where

United States
216
China
33
Spain
29
Egypt
25
Germany
24
Korea, Republic of
22

Who develops what

Add Alopecia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 31 programs from 24 companies, 27 with this as their studies’ main aim; 12 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Applied Biology, Eurofarma Laboratorios and 3SBio here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
MinoxidilRecent, repeated
Evidence
  • NCT07435012 · Triple Hair Inc · Phase 3 · live · comparator · “Minoxidil 5% Topical Solution” · registered Feb 2026
  • NCT07011485 · PDFE Pharma Innovations FZCO · Phase 2 · live · comparator · “Minoxidil 5% Topical Solution” · registered May 2025
  • NCT06501924 · Applied Biology, Inc. · Phase 3 · comparator · “Topical minoxidil 5%” · registered Jul 2024
  • NCT06484881 · Applied Biology, Inc. · Phase 3 · comparator · “Topical minoxidil 5%” · registered Jun 2024
  • NCT05636904 · dermaliq therapeutics inc · Phase 2 · comparator · “Minoxidil 5% Topical Solution” · registered Nov 2022
Industrial Farmacéutica Cantabria, S.A.15% of its industry studiesUS: off-patent, 18 generics marketed45 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
VDPHL01☆ Track3 live phase-3 studies: NCT07146022, NCT06972264, NCT06724614Veradermics, Inc.
CKD-843☆ Track1 live phase-3 study: NCT06916793Chong Kun Dang Pharmaceutical
JXL-069☆ Track1 live phase-3 study: NCT07819435Pelage Pharmaceuticals, Inc.
TH07☆ Track1 live phase-3 study: NCT07435012Triple Hair Inc
MinoxidilApproved: US☆ Track1 live phase-3 study: NCT070809313SBio Inc.

The 5 in phase 3 with the nearest primary completion, of 31 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.VDPHL01 · Veradermics, Inc. · Phase 3 main aimNCT06972264 Safety and Efficacy of VDPHL01 in Males With AGA — primary endpoint: Changes in non-vellus Target Area Hair Counts (TAHC) · 480 enrolled
  • 5 Feb 2027 est.DA-020, hyperforin · Applied Biology, Inc. · Phase 2 main aimNCT07397325 Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia — primary endpoint: Prevention of Hair Loss (Common Terminology Criteria for Adverse Events V5.0) · 60 enrolled
  • Jun 2027 est.VDPHL01 · Veradermics, Inc. · Phase 3 main aimNCT07146022 Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) — primary endpoint: Changes in non-vellus Target Area Hair Counts (TAHC) · 552 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Alopecia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here JAK inhibitors 6 open · Tyrosine kinase inhibitors (TKIs) 6 open · 5-alpha reductase inhibitors 2 open · Corticosteroids 2 open

Coming up

56studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger. 9 (12%) take children under 18. 18 (24%) are for women only and 17 (23%) for men only; 24 (32%) take healthy volunteers.

Recruiting studies that take each age, of 75
AgeWomenMen
104 (5%)4 (5%)
1845 (60%)46 (61%)
3054 (72%)54 (72%)
4057 (76%)55 (73%)
5056 (75%)52 (69%)
6545 (60%)38 (51%)
7532 (43%)25 (33%)
8526 (35%)20 (27%)

Across all 512 studies, recruiting or not: 66% stop at 75 or younger and 57% at 65; 8% take children; 23% are for women only and 28% for men only; 40% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Alopecia studies take

Of 42 phase 2 interventional studies under Alopecia, half reached primary completion within 13 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 110 mo5–57 · 33 studies——
Phase 213 mo9–24 · 42 studies12 mo9–18 · 25 studies—
Phase 319 mo12–59 · 28 studies——
Interventional, no phase12 mo6–27 · 146 studies9 mo5–20 · 61 studies13 mo8–46 · 85 studies
Observational20 mo5–38 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 512. Browse all 512 → or search them.